HC Wainwright Has Optimistic Outlook of PepGen Q1 Earnings

PepGen, Inc. (NASDAQ:PEPG) – Stock analysts at HC Wainwright lifted their Q1 2026 earnings per share (EPS) estimates for shares of PepGen in a research note issued to investors on Thursday, March 5th. HC Wainwright analyst A. Ghosh now expects that the company will post earnings per share of ($0.27) for the quarter, up from their prior estimate of ($0.52). HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for PepGen’s current full-year earnings is ($2.73) per share. HC Wainwright also issued estimates for PepGen’s Q2 2026 earnings at ($0.27) EPS, Q3 2026 earnings at ($0.27) EPS, Q4 2026 earnings at ($0.27) EPS, FY2026 earnings at ($1.09) EPS, FY2027 earnings at ($1.88) EPS, FY2028 earnings at ($1.82) EPS, FY2029 earnings at ($1.43) EPS and FY2030 earnings at ($0.66) EPS.

A number of other research firms also recently issued reports on PEPG. Wall Street Zen upgraded shares of PepGen from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Oppenheimer initiated coverage on PepGen in a research note on Wednesday, February 25th. They set an “outperform” rating and a $15.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of PepGen in a report on Thursday, January 22nd. Finally, Guggenheim increased their price objective on PepGen from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $12.60.

PepGen Stock Performance

Shares of PEPG stock opened at $6.16 on Monday. The company’s 50 day moving average price is $5.90 and its two-hundred day moving average price is $4.85. PepGen has a 52 week low of $0.88 and a 52 week high of $7.80. The company has a market capitalization of $425.72 million, a P/E ratio of -2.56 and a beta of 1.87.

PepGen (NASDAQ:PEPG) last released its earnings results on Wednesday, March 4th. The company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.13.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. AQR Capital Management LLC acquired a new stake in shares of PepGen during the first quarter worth $122,000. Woodline Partners LP acquired a new position in PepGen in the first quarter valued at $1,097,000. Marshall Wace LLP bought a new stake in PepGen during the second quarter valued at $44,000. Qube Research & Technologies Ltd acquired a new stake in PepGen during the 2nd quarter worth about $81,000. Finally, RBF Capital LLC acquired a new stake in PepGen during the 2nd quarter worth about $111,000. Institutional investors and hedge funds own 58.01% of the company’s stock.

About PepGen

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).